Absci (ABSI) DeferredTaxAndRevenue: $0.45 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ABSI Absci Corp ABSI
47 GF Score
Price $8.07
GF Value $0.92
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Absci DeferredTaxAndRevenue?

Absci ABSI -2.06% 47 DeferredTaxAndRevenue is $0.45 Mil as of Mar. 2026. GuruFocus rates ABSI with a GF Score™ of 47/100 and a GF Value™ of $0.92 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Absci's current deferred tax and revenue for the quarter that ended in Mar. 2026 was $0.45 Mil.

Absci DeferredTaxAndRevenue Related Terms

Absci DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Absci's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Absci DeferredTaxAndRevenue Chart

Absci Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial 1.35 0.45 3.17 1.12 0.74

Absci Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.10 0.95 1.08 0.74 0.45
ABSI
47GF Score
Absci Corp ABSI
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $0.45 Mil mean?
Absci (ABSI) has a DeferredTaxAndRevenue of $0.45 Mil as of Mar. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Absci.
Is Absci's DeferredTaxAndRevenue too high?
Absci's current DeferredTaxAndRevenue is $0.45 Mil. Overall, Absci has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Absci's DeferredTaxAndRevenue compare to ANAB and RXRX?
Absci's DeferredTaxAndRevenue of $0.45 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Absci. Absci's current DeferredTaxAndRevenue is $0.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Absci stock overvalued right now?
Based on GuruFocus' analysis, Absci (ABSI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.92, compared to a current price of $8.07 — trading 777.2% above its estimated fair value. The current DeferredTaxAndRevenue is $0.45 Mil. Absci's overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Absci (ABSI), the current DeferredTaxAndRevenue is $0.45 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Absci (ABSI) Overvalued in 2026?

Based on GuruFocus' analysis, Absci stock appears to be overvalued. The current stock price of $8.07 is trading 777.2% above its estimated GF Value™ of $0.92. GuruFocus considers Absci to be Significantly Overvalued.

Key valuation signals for ABSI:

  • DeferredTaxAndRevenue: $0.45 Mil
  • GF Value™: $0.92 vs. price of $8.07 (777.2% above fair value)
  • GF Score™: 47/100 with 3 warning signs

No single metric tells the full story. See the ABSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Absci Business Description

Address 18105 SE Mill Plain Boulevard, Vancouver, WA, USA, 98683
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
47GF Score

Get the complete analysis for ABSI

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.07
Price
$0.92
GF Value